No more NHI reimbursement limits on Zeffix

Published: 2005-12-20 06:58:00

Updated: 2005-12-20 06:58:00

So far GSK's Zeffix, (lamivudine), a B virus hepatitis drug, has been under a restricted NHI reimbursement schedule, only for 2 year medication, but this restriction will be no longer applicable from 2006, indicating that the patient with B hepatitis will get benefits without any term limitation ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK